Lilly (Eli)
LLY SP500 HealthcareKursutveckling (180 dagar)
Kursutveckling vs OMX30
Fundamentala nyckeltal
AI-analys
Kort sikt (3 månader)
58/100Baserat enbart på tekniska signaler.
Lång sikt (3 år)
54/100Baserat enbart på sentiment, inga fundamenta tillgängliga.
Fallback: teknisk=21, sentiment=0. AI-analys ej tillgänglig.
- AI-analys misslyckades
Senaste nyheter
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration a...
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration a...
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration a...
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration a...
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration a...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price ta...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones...
Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that a...
Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that a...
Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that a...
Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that a...
Eli Lilly (NYSE:LLY) has entered a partnership with BioArctic to develop a new neurodegeneration therapy using BrainTransporter drug delivery technology. The collaboration focuses on treatments that a...